Specialty & Oncology November 2014
Uloric Product Information Guide March 2011
Gout is the most common form of arthritis and affects 6.1 million Americans. The primary underlying cause of gout is hyperuricemia. ULORIC 40 mg or 80 mg is approved for the treatment of hyperuricemia in patients with gout.
Click here for PDF.
Diabetes October 2014
Specialty & Oncology September 2014
Pharmacy & Technology August 2014
Specialty & Oncology July 2014
Generic Drug Review June 2014
Specialty & Oncology May 2014
Specialty & Oncology March 2014
Specialty & Oncology January 2014
Oncology November 2013
Diabetes October 2013
Individualizing Therapy for the Patient With Type 2 Diabetes
Oncology September 2013
Pharmacy & Technology Supplement
Oncology July 2013
Generic Drug Review June 2013
Oncology May 2013
Oncology March 2013
Oncology January 2013
Oncology November 2012
Oncology September 2012
Oncology July 2012
BYDUREON Product Information Guide 2012
Generic Drug Review June 2012
Diabetes May 2012
Oncology May 2012
OFIRMEV Product Information Guide April 2012
Compliance April 2012
Oncology March 2012
U.S. Pharmacist is a monthly journal dedicated to providing the nation's pharmacists with up-to-date, authoritative, peer-reviewed clinical articles relevant to contemporary pharmacy practice in a variety of settings, including community pharmacy, hospitals, managed care systems, ambulatory care clinics, home care organizations, long-term care facilities, industry and academia. The publication is also useful to pharmacy technicians, students, other health professionals and individuals interested in health management. Pharmacists licensed in the U.S. can earn Continuing Education credits through Postgraduate Healthcare Education, LLC, accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
Copyright © 2000 - 2015 Jobson Medical Information LLC unless otherwise noted.
All rights reserved. Reproduction in whole or in part without permission is prohibited.